MENLO PARK, Calif. – Verantos, a leader in real-world evidence (RWE) solutions for the life sciences industry, has been recognized as one of North America’s fastest-growing technology companies, ranking 444th on the 2024 Deloitte Technology Fast 500™. This prestigious list, now in its 31st year, highlights the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies across North America based on their revenue growth over the past three years. Verantos stands out as the only company on the list focused exclusively on real-world evidence, underscoring its unique position in the evolving healthcare technology landscape. Real-world evidence refers to data collected from sources outside traditional clinical trials, such as electronic health records, insurance claims, patient registries, and wearable devices. It provides critical insights into how treatments perform in diverse, real-world populations—offering a more comprehensive picture than controlled trials alone. Verantos’ platform enables pharmaceutical and biotech companies, as well as regulators, to leverage this data to inform drug development, improve patient outcomes, and support regulatory submissions. The company’s inclusion on the Fast 500 reflects its rapid growth and innovation in transforming complex, fragmented healthcare data into actionable insights. Verantos has developed a proprietary technology platform that standardizes, de-identifies, and analyzes real-world data at scale, helping clients understand treatment effectiveness across different patient subgroups, long-term safety, and economic impact. This capability is increasingly vital as the healthcare industry shifts toward value-based care and personalized medicine. Verantos’ leadership team attributes the company’s success to its deep domain expertise, advanced data science, and commitment to privacy and compliance. The company operates under strict regulatory standards, ensuring its solutions meet global data protection requirements, including HIPAA and GDPR. Its ability to deliver high-quality, timely RWE has made it a trusted partner for major pharmaceutical companies and health systems. In a statement, Verantos’ chief executive emphasized the growing importance of real-world evidence in modern drug development. “Real-world evidence is increasingly used to augment trial results, providing insight on patient subgroups and real-world outcomes,” he said. “As healthcare becomes more data-driven, the ability to generate reliable, scalable evidence from real-world sources is no longer optional—it’s essential.” The recognition by Deloitte highlights not only Verantos’ financial growth but also its strategic impact on the future of healthcare innovation. With clinical trials often limited in scope and duration, RWE bridges critical gaps by revealing how treatments work in everyday practice, across diverse populations, and over extended periods. This is especially valuable for rare diseases, chronic conditions, and post-market surveillance. Verantos’ ranking also signals a broader trend: the rise of data-centric companies in life sciences. As the industry embraces digital transformation, demand for RWE platforms is growing rapidly. Other companies in the Fast 500 list include leaders in AI, cloud computing, and biotech, but Verantos is the only one focused solely on real-world evidence, making its achievement even more notable. The company plans to use its recognition to expand its platform, invest in new data sources, and strengthen its global presence. With increasing pressure on drug developers to demonstrate value and safety in real-world settings, Verantos is well-positioned to play a central role in shaping the future of evidence-based medicine. As the healthcare ecosystem continues to evolve, Verantos’ success on the Deloitte Fast 500™ serves as a powerful indicator of the growing importance of real-world data in driving innovation, improving patient care, and supporting smarter, more efficient decision-making across the life sciences industry.